Qiagen NV
NYSE:QGEN
Relative Value
The Relative Value of one QGEN stock under the Base Case scenario is 52.82 USD. Compared to the current market price of 41.65 USD, Qiagen NV is Undervalued by 21%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
QGEN Competitors Multiples
Qiagen NV Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
NL |
Qiagen NV
NYSE:QGEN
|
9.2B USD | 4.7 | 27 | 14 | 20.4 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.8B USD | 5.2 | 37 | 22.8 | 33.5 | ||
US |
Danaher Corp
NYSE:DHR
|
182.6B USD | 4.2 | 22.6 | 16.5 | 20.3 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.6B USD | 2.8 | 31.4 | 17 | 26.2 | ||
CH |
Lonza Group AG
SIX:LONN
|
38.1B CHF | 5.7 | 58.2 | 20 | 29.3 | ||
US |
Agilent Technologies Inc
NYSE:A
|
40.4B USD | 6 | 32.7 | 26.1 | 31.4 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
54.8T KRW | 14.8 | 63.9 | 33.7 | 48.5 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 7 | 33.8 | 23.6 | 26.3 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.5B USD | 9 | 44.6 | 30.5 | 36.5 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.4B USD | 3.1 | 41.5 | 17.6 | 27.5 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR | 7.1 | 75.4 | 32.4 | 53.2 |